| Original language | English |
|---|---|
| Pages (from-to) | 13-15 |
| Number of pages | 3 |
| Journal | Annals of Allergy, Asthma & Immunology |
| Volume | 124 |
| Issue number | 1 |
| Early online date | 11 Oct 2019 |
| DOIs | |
| Publication status | Published - Jan 2020 |
Cite this
}
Anti-inflammatory reliever therapy for asthma. / Lipworth, Brian (Lead / Corresponding author); Chan, Rory; RuiWen Kuo, Chris.
In: Annals of Allergy, Asthma & Immunology, Vol. 124, No. 1, 01.2020, p. 13-15.Research output: Contribution to journal › Article
TY - JOUR
T1 - Anti-inflammatory reliever therapy for asthma
AU - Lipworth, Brian
AU - Chan, Rory
AU - RuiWen Kuo, Chris
N1 - Dr Lipworth reported receiving grants, personal fees, and nonfinancial support from Astra Zeneca (UK); grants, personal fees, and nonfinancial support from Chiesi (Italy); and other support from GSK (UK) during the conduct of the study and grants, personal fees, and nonfinancial support from Boehringer Ingelheim (Germany) and personal fees from Sanofi (France), Teva (Israel), Novartis (Switzerland), Cipla (India), Circassia (UK), Vectura (UK), Glenmark (UK), Dr Reddys (India), Lupin (USA), Genentech (USA), outside the submitted work. Dr Kuo reported receiving personal fees from Circassia (UK) and AstraZeneca (UK) outside the submitted work. No other disclosures were reported.
PY - 2020/1
Y1 - 2020/1
U2 - 10.1016/j.anai.2019.10.002
DO - 10.1016/j.anai.2019.10.002
M3 - Article
C2 - 31610234
VL - 124
SP - 13
EP - 15
JO - Annals of Allergy, Asthma & Immunology
JF - Annals of Allergy, Asthma & Immunology
SN - 1081-1206
IS - 1
ER -